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Abstract 
Background: Erythrocyte MCV might be used as an inexpensive marker to predict and 
optimize the efficacy and tolerability of thiopurine therapy in IBD patients. 
Aim and methods: This retrospective observational study aimed to assess the monitoring 
performances of MCV in patients under 3 months or more thiopurine treatment followed up 
in the Swiss IBD Cohort Study. All available MCV, white blood cells (WBC) and 6 
thioguanine nucleotide (6TGN) measurements, among others, were recorded. An IBD 
“flare” was defined as a composite outcome encompassing treatment change, 
colonoscopy, histology, CT scan or MRI reports showing active IBD lesions, occurrence of 
intestinal surgery and IBD-related hospitalisations. Whether MCV measurements predicted 
efficacy of thiopurine treatment was investigated by assessing the statistical association 
between the occurrence of IBD “flares”, and the current or recent MCV values, taking into 
account the patient clustering and longitudinal aspect of data.
Results: 140 patients (77 women), mean age 38 years (17-74), 104 diagnosed with 
Crohn’s disease, 36 with ulcerative colitis, mean disease duration 8 years (0.25-36), 
receiving either azathioprine (n=125) or 6-mercaptopurine (n=15) were included, most of 
them over 3-year follow up.
Thiopurines increased mean patient MCV by an average 5.8±5.2 fL, while 
patientsfluctuated by ±4.3 fL around their individual mean (p<0.001). They decreased 
WBC  by an average of 2.4+/- 2.6 G/L (p<0.001).
Significant associations were observed between the probability of flare occurrence and low 
current MVC (p=0.017) or high current WBC (p=0.009) and, with a relative risk of 3.7% for 
every fL of MCV decrease or 8% for every G/L of WBC increase. Both markers revealed 
some memory effect. 
Despite this, the performance of MCV and WBC to predict IBD “flare” remained rather 
limited, as it is less accurate than the 6-TGN-level , although only determined in a 
subgroup of patients in this study. 
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Conclusion MCV and WBC deserve to be observed to check and monitor therapeutic 
exposure to thiopurine agents in IBD patients. Unfortunately, their predictive performance 
precludes their privileged use for optimization of therapy. Further prospective studies 
should suitably include the systematic measurement of metabolite concentration. 
Key words : MCV, Thiopurine, IBD, Monitoring, Flare
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Background
About 12 000 patients are affected by inflammatory bowel disease (IBD: Crohn’s disease, 
ulcerative colitis, indeterminate colitis) in Switzerland (1). Among them, approximately 45% 
receive thiopurines as immunosuppressant treatment (azathioprine 40%, 6-
mercaptopurine 5%). 
As demonstrated in several controlled trials versus placebo (2; 3; 4) and meta-analyses (5; 
6; 7), thiopurines (azathioprine and 6-mercaptopurine) are effective as steroid sparing 
drugs and for maintenance of remission in IBD (40; 41; 42; 43). Alleviation of clinical 
symptoms and signs of inflammation as well as, more recently, mucosal healing, represent 
the main objectives of the treatment (44). 
Azathioprine (AZA) and its metabolite 6-mercaptopurine (6-MP) are purine base analogues 
that inhibit biosynthesis and incorporation of purine nucleotides in cells during mitosis (8). 
Consequently, they interfere with the maturation of not only immunocompetent cells, but 
also erythroid precursors (7), thus increasing red blood cells MCV (14; 15; 16). Similarly, 
they affect myeloid precursors, making neutropenia a well-known dose-dependent effect of 
thiopurine therapy. 
MCV is a measurement of the average red blood cell size and is calculated by dividing the 
haematocrit by the red blood cell count (16). The widely used automated blood cell 
counters make such marker readily available and relatively inexpensive. 
Thiopurines are prodrugs given on the long term with a complex metabolism characterized 
by large inter-individual variability (9), including variable bioavailability (10,11,14). 
Thiopurine methyltransferase (TPMT), the cytosolic enzyme that metabolises azathioprine 
in vivo, exhibits genetic polymorphism. The risk of azathioprine induced myelosuppression 
corrélâtes with intermediate or low TPMT activity. As in most long-term therapies, patient 
adherence represents a potential issue. Such treatments ideally require methods for 
control of efficacy. Chronic care could potentially be improved, and possibly at reduced 
cost, by implementing rational monitoring strategies (12).
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Recently, a study established that MCV in patients under effective azathioprine treatment 
was significantly greater than in those for whom the treatment was rated as ineffective. 
The authors suggested that measurements of variation in MCV values could serve as a 
guide to adjust the dose in patients with Crohn’s disease (15). In the past, investigators 
had already reported that an increase in MCV was commonly observed during thiopurine 
therapy, and that the change in the MCV may represent a helpful response marker in 
patients during thiopurine therapy for Crohn's disease (11). Two further studies confirm 
that patients experiencing a clinical response to treatment with thiopurines have greater 
MCV increases than non-responders, suggesting that a change in MCV anticipates the 
therapeutic response in patients with Crohn’s disease (10), and that MCV might be used 
as a cost effective marker to guide 6-mercaptopurine therapy in IBD (13). 
Erythrocyte MCV, known to increase under thiopurines, might thus be used as an 
inexpensive monitoring marker to predict and optimize the efficacy and tolerability of 
thiopurine therapy in IBD patients.
The present study is a retrospective observational analysis aimed to assess the potential 
monitoring performances of MCV and WBC in patients under azathioprine or 6-
mercaptopurine treatment followed up by the Swiss Inflammatory Bowel Disease Cohort 
Study (SIBDCS) in three participating centres (University Hospital Centre of Lausanne, 
Clinique la Source in Lausanne, and Hôpital Neuchâtelois). 
Material and Methods
Patients
The Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) provided the population 
sample. The SIBDCS, running from 2005, is a national disease-oriented prospective 
cohort that brings together 6 main centres (Basel, Bern, Geneva, Lausanne, Zurich, St 
Gallen), hospital centres  and gastroenterologists in private practice who agreed to 
participate. In October 2011, around 2200 patients gave their consent to participate in this 
study. Inclusion criteria target IBD patient with a diagnosis established at least 4 months 
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prior to inclusion or having had at least one recurrence of their symptoms, permanently 
residing in Switzerland or having contracted Swiss health insurance, and being treated on 
a regular basis in Switzerland. Participation is not restricted by age or sex; it is voluntary 
and relying on individual motivation. Diagnosis, based on Lennard–Jones criteria (36), can 
be confirmed by radiological, endoscopic and histological findings or surgery (37). Our 
study specifically included IBD patients (Crohn’s disease or ulcerative colitis) receiving 
prolonged (>3 months) treatment of azathioprine or 6-mercaptopurine, for whom a medical 
record could be consulted from either hospitals or physicians in our regional area. 
Treatments
All Azathioprine and/or 6-mercaptopurine dosages were collected retrospectively from 
patient charts. Treatment allocation, doses, follow up and co-medication were defined by 
physicians in charge of the patients. We had no information on treatment compliance. 
Observations
Clinical and biological data routinely recorded into the SIBDCS data base are, among 
others, : gender, age, weight, diagnosis, date of diagnosis, severity of disease as defined 
by the Crohn’s disease activity index (CDAI) for Crohn’s disease (17) and by the Modified 
Truelove & Witts activity index (MTWAI) for ulcerative colitis (18), clinical course 
(phenotype according to Montreal classification for state of disease), treatment (dose, 
duration and evolution), therapy adverse effects, past therapy, supplementation therapy 
(iron, Vit.B12, folic acid), number of IBD flares, complications and/or hospitalisations due 
to the IBD. The following laboratory parameters are recorded in the database on a yearly 
basis: leukocytes count, haemoglobin (Hb), haematocrit (Ht), C-reactive protein (CRP), 
erythrocytes sedimentation rate ESR, ferritin, vitamin B12, folic acid, alkaline phosphatase 
and albumin.
In addition, the medical records of the patients included were reviewed manually to record 
the following supplemental data, when available: MCV, azathioprine and/or 6-
mercaptopurine dose, haemoglobin count, haematocrit, erythrocytes, leukocytes count 
(WBC), neutrophils and platelets counts, mean platelet volume, ferritin, Vitamin B12, folic 
acid, C-reactive protein, erythrocyte sedimentation rate, 6-thioguanine nucleotide (6-TGN) 
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and 6-methylmercaptopurine (6-MMP) blood concentrations (these thiopurine metabolites 
were considered to have been determined at the end of a dosage interval, in the absence 
of precise information regarding last dose intake time). Different laboratories in Switzerland 
measured MCV and we have no precise information on the method of measurement or on 
the laboratories validation. However, MCV is mostly measured using volume-sensitive 
automated blood cell counters by optical means.
Blood tests were collected through medical records with one-week interval or more from 
the beginning of the thiopurine treatment. If available the two last blood tests before 
treatment were collected, respecting also a one-week interval.
Medical treatment changes, colonoscopy, histology, CT scan and MRI reports, occurrence 
of intestinal surgery, hospitalisation due to the IBD, occurrence of extra-intestinal 
symptoms (uveitis, erythema nodosum, pyoderma gangrenosum, severe arthritis), 
presence of stenosis and /or dilatation were also timely recorded.
Composite outcome 
An IBD event or “flare” was defined as a composite outcome encompassing any 
introduction of new IBD medical treatment (anti-TNF therapy, methotrexate, steroid, 
mesalazine), active IBD lesions shown on colonoscopy, histology, CT scan, MRI report, 
occurrence of intestinal surgery and hospitalisation related to IBD, occurrence of stenosis 
and/or dilatation, and a CDAI greater then 150 or a MTWAI greater or equal to 10. 
Statistical analysis 
All collected variables were subjected to descriptive analysis. Results were expressed as 
mean or median (± standard deviation or range) for numerical variables and as±
 percentages for qualitative variables. A p-value less than 0.05 was considered statistically 
signiﬁcant during comparisons with standard tests (T-test, linear correlation). 
The effects of time and thiopurine dose on MCV and WBC values were explored using 
multilevel mixed effect linear regression analysis (accounting for hierarchical random 
patient effect). A variogram analysis was also applied to the time sequences of MCV and 
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WBC, to observe the time-related change in variance between initial on-treatment values 
and subsequent values; assuming patient-specific linear long-term trends for these 
markers, it is appropriate to fit the variograms with a quadratic model for time, again using 
multilevel mixed effect linear regression (39). Finally, in a nested case-control inspired 
approach, the effect of MCV, WBC and further factors on the probability of IBD event 
occurrence was explored using multilevel (hierarchical) mixed effect logistic regression 
analysis (accounting for random patient susceptibility). Calculations were performed using 
the Excel (Microsoft, 2011) and STATA software (v. 11, StataCorp, College-Station TX, 
2007). 
Results
Study population and treatments
We were able to include 140 patients (77 women), with a mean age of 38 years (range: 
17-74), 104 diagnosed with Crohn’s disease and 36 with ulcerative colitis, with a mean 
disease duration 8 years (0.25-36), currently receiving either azathioprine (n=125) or 6-
mercaptopurine (n=15), most of them with 3-year follow up. We recorded a total of 1594 
MCV determinations and 256 “flares” in these patients; pre-treatment MCV values were 
available in only 61 patients. Among patients under azathioprine, 54 had 6-TG and 6-MMP 
blood determinations. Mean daily azathioprine dosage was 135 mg (SD: ± 48 mg). Mean 
daily 6-mercaptopurine dosage was 72 mg (+/- 25 mg).
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Number of patients 140 
Women : Men 55% : 45% 
Mean age (range) 38 (17 – 74) 
Crohn’s disease : Ulcerative colitis 75% : 25% 
Mean disease duration in years (range) 8 (0.25 – 36) 
Azathioprine : 6-mercaptopurine 90% : 10% 
Number of MCV determinations per patient 
(mean ± SD)
11.6 ± 7.6 (0 – 39) 
Number of WBC determinations  per patient 11.6 ± 7.5(0 – 39)
Daily azathioprine dose (mean ± SD) 135 ± 48 mg
Daily 6-mercaptopurine dose 72 ± 25 mg
Number of “flares” reported per patient 1.8 ± 2.2 (0 – 12) 
Table 1 : Characteristics of study population, treatments and outcomes 
Factors affecting the occurrence of “flares”
Time related evolution of “flare” occurrence 
Under the hypothesis of a similar intensity of follow up between studied patients, we 
observed a patient factor that explained 24% of the variability in “flare” occurrence 
(p<0.001). 
There seemed to be no significant time trend increase in the occurrence of “flares”, with a 
+3%/year slope (p=0.43)
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Influence of current and past therapy on the occurrence of “flares” 
The occurrence of events was different under AZA and 6-MP, the latter being associated 
with a greater risk of “flare” (Relative risk : 1.5, p=0.05); this is however likely to reflect 
therapeutic decisions taken in patients with frequent recurrences, rather than a proper 
characteristic of the drugs. 
We observed no association between the daily dosage of AZA and 6-MP and the 
frequency of “flare” occurrence (p=0.17, resp. 0.74). If we combine the current AZA daily 
dose with the mean dose over one to twelve month before, both  it then appears 
significantly related to flare occurrence, with opposite effects. This might well result from 
therapeutic decisions taken in patients with frequent recurrences. 
We did not find any influence of the 6-MP doses history on flares frequency.  
Time related evolution of azathioprine and 6-mercaptopurine doses 
We did not observe any clear time trend in thiopurine daily dosages, the slight increase 
observed in mean azathioprine or 6-mercaptopurine (Azathioprine 2.7 mg/year, 6-
mercaptopurine 1.9 mg/year) did not reach significance (p= 0.08, resp. 0.11). Neither did 
we observe any signiﬁcant time trend in metabolites concentration monitoring. On the 
other hand, we did not observe any effect of a change in dosage during the past months.
Factors affecting MCV and WBC 
Global effect of the treatment on MCV and WBC 
Thiopurines increased mean MCV by an average 5.8±5.3 fL in patients providing pre-
treatment values, while patients fluctuate by ±4.3 fL around their individual mean (p<0.001 
for patient clustering). A patient effect thus explains 59% of the variance (however, as the 
values are differences with pre-treatment baseline, up to 50% may be due to variability 
from the baseline value, thus leaving a mere 9% that accounts for individual sensitivity). 
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Figure 1: Distribution of MCV changes in fL from pre-treatment baseline (MCV)
The same approach applied to WBC also revealed a significant patient effect (p<0.001), 
the patients decreasing by an average of 2.4 ± 2.6 G/L under treatment from their pre-
treatment value, while fluctuating by 3.2 G/l around their individual mean. The patient 
effect explains 50% of the variance (which presumably results from variability in baseline 
levels, thus leaving no variability in individual sensitivity).
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Figure 2: Distribution of WBC changes (in 109/L) from pre-treatment baseline (ΔWBC)
Influence of the thiopurine type (AZA or 6-MP) on MCV and WBC 
6-MP appeared to increase MCV by an additional 3.6 fL compared to AZA (p<0.001). 
Conversely, we did not observe any influence of the thiopurine type on WBC (p=0.88). 
Influence of treatment duration on MCV and WBC
Independently of drug dosage, which did not show any time-related trend, MCV tended to 
increase along treatment duration (slope: 1.2 ± 1.3 fL/year, p<0.001), with a significant 
heterogeneity in individual slopes and intercepts (p<0.001). A similar association was also 
observed with the WBC (negative slope:  -0.25 +/- 0.19 G/L/year, p<0.001), however 
without significant slope heterogeneity (p=0.09).
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Figure 3: Individual MCV and WBC values and patient specific linear trends 
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MCV and WBC variogram
We estimated the time-related increase in variance between the first ongoing treatment 
MCV or WBC value and the subsequent MCV, WBC values measured during treatment.
For MCV, the instantaneous (extrapolated to time zero) variance was 2.9 ± 4.2 fL. Only 
after 4 years did the increase in variance reach a magnitude similar to the instantaneous 
variance. This means that roughly 4 years would have to be waited before remeasuring 
MCV to have a reasonable chance (50%) to impute a change to a real drift of MCV value 
in the patient. 
For WBC we could not find any time related tendency, there was no drift of the variogram 
along time, in accordance with the absence of heterogeneity in patient trajectories.  
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Figure 4 : MCV and WBC variograms along time; variances in Δ
MCV are appropriately fitted by hierarchical quadratic regression, while variances in Δ 
WBC show no significant time related trend 
Influence of current AZA doses on MCV and WBC 
Patients under AZA showed a significant association between their current AZA dosage 
and MCV, amounting to 0.044 fL per mg/day (p<0.001), while accounting for patient effect 
on MCV level. The same association was observed for WBC, showing a decrease by 
0.017 G/L per mg/day (p<0.001). We found the same association looking either at raw 
values or at changes of MCV and WBC from the corresponding baseline pre-treatment 
value. A random intercept linear model fitted the data adequately, accounting for patient 
effect without indication of variability in individual dose-response slopes. 
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Δ
Figure 5: Association between AZA dose and MCV and WBC (individual dose-response 
lines are drawn only for patients experiencing dosage changes)
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Influence of current 6-MP doses on MCV and WBC 
Patients under 6-MP showed as well a significant association between current 6-MP 
dosage and MCV, of 0.093 fL per mg/day (p<0.001). Here again, we found the same 
association looking either at raw values or at changes of MCV compared to the basal pre-
treatment value. 
Patients under 6-MP, showed a similar but non-significant association between actual 6-
MP doses and WBC, possibly due to the small number of individuals. 
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Figure 6: Association between 6-MP doses and MCV and WBC (individual dose-response 
lines are drawn only for patients experiencing dosage changes)
Influence of the history of AZA and 6-MP doses on MCV and WBC 
On analysing the sequence of integrated AZA doses over the past months, we observed 
an association with MCV and WBC (p<0.001) increasing up to 4 month before 
determination. A similar association was observed for the change of MCV and WBC from 
the baseline value. 
On combining current AZA doses with the cumulated dose over one or several past 
months, we observed a stronger association with the integrated dose (p<0.001), with a 
corrective influence of the current dosage.
Similarly, the sequence of integrated 6MP doses over the past months revealed an 
association with MCV (p<0.001), increasing up to 2 months, and with WBC (p=0.037), 
detectable up to 6 months before determination. Combining current 6MP doses with the 
mean dose over one or several past months revealed a stronger association with the 
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integrated dose (MCV p<0.001 ; WBC p=0.092), without any more influence of the current 
dose.
Influence of the concentrations of 6-thioguanine nucleotide (6TGN) and 6-
methylmercaptopurine (6MMP) on MCV and WBC 
In the subset of 102 patients having provided thiopurine metabolites concentration results 
under AZA, MCV appeared to be correlated with 6TGN concentrations, with a slope of 
0.0082 fL per pmol/8·108 erythrocytes (p=0.016, hierarchical linear regression). This 
association was stronger than with AZA dose in those patients (p=0.017). MCV was not 
correlated with 6MMP. Conversely, WBC values revealed no correlation with 6TGN 
concentrations, but were slightly associated with 6MMP concentrations, however with a 
rather flat slope of  -0.00012 G/L per pmol/8·108 erythrocytes (p=0.04). 
There were not enough concentration measures in patients receiving 6MP to draw a 
conclusion. 
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Figure 7: Association between 6-TGN concentration and current MCV, and between 6-
MMP concentration and current WBC value (individual concentration-response lines are 
drawn only for patients with several measurements). 
Finally, MCV revealed a moderate correlation with ferritin levels (determined on 490 
occasions) but no association with either vitamin B12 (334 determinations) or folic acid 
(287 determinations), and appeared to be negatively correlated with C-reactive protein 
levels (1078 determinations). On the other hand, WBC counts were positively correlated 
with C-reactive protein levels. 
Relationship between MCV, WBC and flares
Current MCV or WBC and flare occurrence 
Our hierarchical logistic regression analysis found a significant association between a low 
current MVC value and the probability of flare occurrence, with an odds ratio of 0.964 
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corresponding to a relative risk of 3.7% for every fL of decrease in MCV (p=0.017). 
Similarly, a higher current WBC level was associated with a higher probability of flare with 
an odds ratio of 1.08, translating into a 8% increase for every supplemental G/L of WBC 
(p=0.009).
We observed no further relevant associations combining MCV or WBC with time, AZA or 
6MP doses, their history or their change during past months (analyses not detailed here). 
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Figure 8: Current MCV or WBC and contemporaneous flare occurrence (0 = no flare, 
1 = flare on measurement time) 
The MCV or WBC effect on the prediction of current flare can also be represented with 
receiver operating characteristic (ROC) curves, showing the rather limited predictive power 
of MCV, and the absence of real predictive power of WBC regarding the occurrence of 
flares.
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Figure 9: ROC curves for current MCV and WBC levels in flare prediction
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History of MCV or WBC and flares occurrence 
The MCV effect appeared to be maximal for current MCV and decreased progressively for 
MCV values integrated over longer duration, losing statistical significance after one month. 
Conversely, changes in mean MCV between the current and the previous months 
improved the prediction independently from current MCV (p=0.04). Changes over 2x2 
months or 2x3 months were non-informative, though. 
Looking for a similar memory effect of WBC prediction of flares, we observed an 
association increasing up to the mean of 3 months (p=0.025). Change in mean WBC over 
2x2 months or 2x3 months improved prediction independently from the current WBC. On 
the contrary, WBC change between the current and the previous months was non 
informative. 
Applying a similar approach to changes of MCV compared to pre-treatment value, when 
available, failed to identify this difference as a flare predictor (p=0.44). Conversely, for 
patients having provided a value of WBC before treatment, we could observe that WBC 
difference versus baseline under thiopurine treatment was a flare predictor (p=0.017). 
Current 6 thioguanine and 6 mercaptopurine concentration and occurrence of flare
This analysis showed an association, however of limit significance (p=0.05) between low 
levels of the 6TGN metabolite concentrations and the probability of flare occurrence, on 
pooling AZA and 6MP treatments. However, this evaluation was based on only 124 
measures, thus limiting its statistical power. Some association persisted over up to 6 
months on relating the current occurrence of flare with past concentration determinations. 
The levels of the 6MMP metabolite revealed no correlation with flare occurrence (p=0.2). 
We observed no further relevant trend combining 6TGN, 6MMP concentration with time, 
AZA or 6MP doses, their history or their change during past months (analyses not detailed 
here). 
The 6TGN and 6MMP based predictions of a current flare can also be represented with 
ROC curves. This analysis reveals a clearly better performance for 6TGN concentrations 
than for MCV or WBC, while the levels of 6MMP are not predictive of flare occurrence.
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Figure 10: ROC curves for current 6TG and 6MMP concentrations for flare prediction
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The occurrence of flare was not associated with the past history of 6TGN, 6MMP 
concentrations. 
Finally, “flares “also tended to occur more frequently in association with high C-reactive 
protein (p=0.001, 1006 determinations analyzed by mixed-effect linear regression 
accounting for patient effect) or sedimentation rate level (p=0.003, 267 determinations), 
and with low hematocrit or haemoglobin concentration (p=0.007) (results not detailed). 
None of these covariables improved the prediction of flare occurrence by MCV or WBC 
values.  
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Discussion
MCV is a measure of the average red blood cell size and is calculated by dividing the 
haematocrit by the red blood cell count. As shown in previous studies, an increase in MCV 
is commonly observed during thiopurine therapy (11; 16). This study aimed to assess 
whether this change in MCV could be used as a monitoring tool during thiopurine therapy. 
In parallel, we analyzed the performances of WBC, a marker usually followed up to detect 
toxicity, regarding treatment efficacy. 
Macrocytosis is a frequent side effect seen in therapies such as azathioprine, sulfalazine, 
other sulfa-based medications and methotrexate even in patients with normal vitamin B12 
and folate concentration, and it is accompanied with megaloblastoid changes in bone 
marrow (21; 29), primarily in erythroid precursors (35). The mechanism for this increase in 
MCV is presumably mediated by interference with DNA synthesis and resulting inhibition of 
cell proliferation and maturation (34). Clinicians have anecdotally noted macrocytosis in 
patients treated with thiopurine, but little has been reported in the medical literature. It may 
take at least three months of thiopurine therapy before an increase in MCV is observed 
(11; 30), in line with the normal erythrocyte life span of 120 days. 
We confirm that MCV consistently and dose-dependently increases under thiopurines 
treatment by an average of about 6 fL. This effect tends to become more pronounced over 
treatment duration, with patients following variable individual trajectories along the time. 
This biomarker could thus be observed to confirm and monitor therapeutic exposure. 
However, the predictive performance of MCV regarding the occurrence of IBD event 
remains fairly limited, leaving this marker with a questionable role for clinical optimization 
of thiopurines treatment. Expressing ongoing-treatment MCV values as differences versus 
pre-treatment baseline does not improve their predictive value either. Interestingly, while 
the effect on MCV seemed related with the history of thiopurine exposure over several 
months, the occurrence of IBD flares appeared exclusively correlated with current MCV 
level, without association with previous values. The inertia characterising MCV changes 
seems thus to have no counterpart regarding treatment efficacy. While low iron stores, 
reflected in ferritin levels, tended to counteract the effect of thiopurines on MCV by 
promoting microcytosis, neither vitamin B12 nor folic acid appeared to play any 
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confounding role regarding MCV levels. 
Due to reversible myelosupression (27) monitoring for cytopenias, especially leukopenia, 
is essential in patients taking thiopurine. Physicians recommend weekly complete blood 
counts for the initial month of drug therapy with monthly blood count checks thereafter 
(28).
More frequent remission and more rapid achievement of remission has been described 
after the development of leukopenia, while the practical significance of leukopenia or 
neutropenia for treatment monitoring remains rather controversial (4; 24; 25; 31; 32; 33). 
Our investigation found a dose dependent, significant leukopenia by an average of 2.4 G/L 
under treatment. Despite an interesting association between flare occurrence and the 
current level and history of WBC count, we found a negligible predictive performance of 
WBC regarding the occurrence of flare, as illustrated by our ROC analysis. WBC levels 
tended to decrease over treatment duration but, unlike MCV, they revealed no individual 
variability among patient trajectories. This observation is in line with the much shorter 
kinetics of WBC turnover, and means that delaying WBC check is of no interest to capture 
any progressive, mid- or long-term drift. 
Measurement of thiopurine metabolite concentration for optimization of drug therapy was 
not infrequently requested in our study patients, although its interest for therapeutic 
monitoring remains controversial (22). Some authors found no predictive value of 
thiopurine metabolites for clinical response (23; 26). Like other studies that suggest a 
correlation between 6-TGN concentrations and clinical response (24; 25), our investigation 
found an association with the occurrence of flare, which appeared stronger than for MCV, 
although still moderate. Noticeably, 6-TGN concentration also correlated with MCV, better 
than did AZA dosage. This points clearly towards the importance of pharmacokinetic 
variability to explain variations in both treatment response and MCV changes. Moreover, 
the association between 6-TGN concentration and flare occurrence remained stable over 
up to 6 months of time lag. This tends to confirm the potential interest of 6-TGN 
measurement for the therapeutic monitoring of thiopurine therapy. While this 
pharmacokinetic marker appears superior to MCV, it is however more costly and 
technically demanding, thus raising cost/utility issues. Circulating concentrations of 6MMP 
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were associated neither with flare occurrence, nor with MCV levels, but they slightly 
correlated with WBC decrease. 
The main limitations of our study are the limited number of patients studied (140), its 
retrospective design, the absence of structured sampling schedule and of a central 
laboratory, and the necessity of manual recording especially for MCV data. It is possible 
that inflammatory status or iron stores of the patients confounded to some extent the MCV 
values observed. Vitamin B12 or folate deficiency might also have affected MCV without 
relation with efficacy or dosage of thiopurine drugs, although we found no indication for 
this. Chronic alcohol consumption could also directly affect MCV (38), but no 
corresponding information was available regarding our study patients to take into account 
this potential confounding factor. 
The absence of a uniform definition of IBD flare in the literature, due to the proteiform 
clinical manifestations of this disease and the absence of specific diagnostic tests, also 
represented a difficulty, that obliged us to create a composite outcome using available 
clinical criteria. 
Another potential bias reported in studies using corticosteroid sparing or withdrawal (31; 
32) as a criterion to define remission is that the fall of leucocytes could be explained by the 
decrease of steroid dose, independently of thiopurine treatment. The fact that our patients 
where under thiopurine treatment from at least 3 month would however diminish the risk of 
a such bias. 
In conclusion, MCV and WBC are markers that deserve attention to check and monitor 
therapeutic exposure to thiopurine drugs in IBD patients. However, their predictive 
performance regarding the occurrence of IBD events seems too limited to recommend 
them as a privileged monitoring tool for treatment optimization. Further prospective studies 
evaluating the systematic measurement of metabolite concentration might better contribute 
to further improve efficacy and refine dosage adjustment during thiopurine therapy. 
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